Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Total Liabilities
Everything the company owes to creditors and other parties.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 263.9% from a year ago
Total liabilities stood at $5.24M at the end of Q1 FY2026, up 263.9% from a year earlier and up 159.6% from the prior quarter. Over 3 fiscal years it compounded at +97.2% a year.
Context
- Total liabilities amounted to 49.8% of total assets at the end of Q1 FY2026, down 2.5 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +263.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.02M USD
- Year-over-year change
- +29.3%
- 4-year CAGR
- +51.3%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.02M | +29.3% |
| FY2024 | 2024-12-31 | 1.56M | +429.8% |
| FY2023 | 2023-12-31 | 294.41K | +12.0% |
| FY2022 | 2022-12-31 | 262.91K | -31.7% |
| FY2021 | 2021-12-31 | 385.17K | — |
Total Liabilities vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +263.9% is the 2nd highest of 9, against a peer median of +5.9%.
- Total liabilities amounts to 49.8% of total assets for GLSI, versus a peer median of 92.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $414.44M USD | -20.7% | +2.5% | 222.3% | |
| Mar 2026 | $398.86M USD | +265.4% | +177.3% | 330.4% | |
IRDOpus Genetics, Inc. | Mar 2026 | $112.62M USD | +161.3% | +133.2% | 168.6% |
| Mar 2026 | $30.65M USD | -15.5% | -3.5% | 11.3% | |
| Mar 2026 | CA$13.29M CAD | +0.6% | +13.0% | 162.9% | |
| Mar 2026 | $11.45M USD | +11.2% | +84.9% | 12.0% | |
| Mar 2026 | $6.51M USD | +36.2% | +30.4% | 21.9% | |
| Mar 2026 | $6.23M USD | -44.5% | +11.5% | 17.2% | |
| Mar 2026 | $5.24M USD | +263.9% | +97.2% | 49.8% | |
| Peer median (excluding GLSI) | — | +5.9% | +21.7% | 92.4% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.